SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001576885-24-000044
Filing Date
2024-03-26
Accepted
2024-03-26 07:42:49
Documents
21
Period of Report
2024-03-26
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abos-20240326.htm   iXBRL 8-K 28707
2 EX-99.1 abos-fy2023pressreleasef.htm EX-99.1 23254
6 abos-fy2023pressreleasef001.jpg GRAPHIC 220556
7 abos-fy2023pressreleasef002.jpg GRAPHIC 248027
8 abos-fy2023pressreleasef003.jpg GRAPHIC 218056
9 abos-fy2023pressreleasef004.jpg GRAPHIC 249664
10 abos-fy2023pressreleasef005.jpg GRAPHIC 126898
11 abos-fy2023pressreleasef006.jpg GRAPHIC 82260
12 abos-fy2023pressreleasef007.jpg GRAPHIC 130050
  Complete submission text file 0001576885-24-000044.txt   1946093

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abos-20240326.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abos-20240326_lab.xml EX-101.LAB 22530
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abos-20240326_pre.xml EX-101.PRE 13043
24 EXTRACTED XBRL INSTANCE DOCUMENT abos-20240326_htm.xml XML 2809
Mailing Address 427 PARK ST. CHARLOTTESVILLE VA 22902
Business Address 427 PARK ST. CHARLOTTESVILLE VA 22902 925-368-8508
Acumen Pharmaceuticals, Inc. (Filer) CIK: 0001576885 (see all company filings)

IRS No.: 364108129 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40551 | Film No.: 24780929
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)